[Correction of metabolic disorders of the myocardium in acute myocardial infarct as an important factor in preventing the development of circulatory insufficiency].
Sinitsyn
S P
SP
D000818:Animals; D007611:Aprotinin / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005971:Glutamates / Q000627:therapeutic use; D018698:Glutamic Acid; D006333:Heart Failure / Q000517:prevention & control*; D007052:Ibuprofen / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy*; D009206:Myocardium / Q000378:metabolism*; D009277:Nandrolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D009543:Nifedipine / Q000627:therapeutic use; D011195:Potassium Magnesium Aspartate / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011817:Rabbits; D012978:Sodium Oxybate / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D005971:Glutamates; D014810:Vitamin E; D018698:Glutamic Acid; D009277:Nandrolone; D012978:Sodium Oxybate; D011195:Potassium Magnesium Aspartate; D007611:Aprotinin; D011433:Propranolol; D000077603:Nandrolone Decanoate; D009543:Nifedipine; D001205:Ascorbic Acid; D007052:Ibuprofen
Korrektsiia metabolicheskikh narusheniĭ v myshtse serdtsa pri ostrom infarkte miokarda kak vazhnyĭ faktor preduprezhdeniia razvitiia nedostatochnosti krovoobrascheniia.